Goldman Sachs’s Precigen PGEN Stock Holding History

Goldman Sachs’s Portfolio PGEN Stock Details PGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-46,000	Closed	-$301K	–	5373
2018 Q4	$301K	Hold	46,000	–	–	﹤0.01%	4634
2018 Q3	$792K	Hold	46,000	–	–	﹤0.01%	4178
2018 Q2	$641K	Buy	+46,000	New	+$777K	﹤0.01%	4365
2016 Q4	–	Sell	-294,426	Closed	-$8.18M	–	7027
2016 Q3	$8.18M	Sell	294,426 -623,764	-68%	-$16.5M	﹤0.01%	2619
2016 Q2	$22.4M	Buy	918,190 +877,830	+2,175%	+$24.9M	0.01%	1713
2016 Q1	$1.36M	Hold	40,360	–	–	﹤0.01%	3815
2015 Q4	$1.21M	Buy	40,360 +13,117	+48%	+$442K	﹤0.01%	4114
2015 Q3	$859K	Buy	+27,243	New	+$1.33M	﹤0.01%	4619
2015 Q1	–	Sell	-209	Closed	-$6K	–	7226
2014 Q4	$6K	Buy	+209	New	+$4.58K	﹤0.01%	7062

Other funds holding PGEN

Patient Capital Management Baltimore, Maryland $3.05B AUM 42.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's PGEN Position: Q2 2026 in Review

Goldman Sachs increased its Precigen (PGEN) stake by 1.7% in Q2 2026, buying an estimated $242K and bringing the position to 3,406,456 shares worth $19.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2663.

Goldman Sachs first reported a position in PGEN in Q3 2013 and has held it in 50 quarters since. 210 funds tracked by Wall St. Rank hold PGEN as of Q2 2026.

Goldman Sachs held 3,406,456 shares of Precigen worth $19.4M as of Q2 2026.
Goldman Sachs bought 55,979 Precigen shares in Q2 2026, an estimated $242K.
Precigen made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2663 holding.
Goldman Sachs first reported a position in Precigen in Q3 2013 and has held it in 50 quarters since.
210 funds tracked by Wall St. Rank held Precigen as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.